NCT05673200 2026-05-13Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast CancerNational Cancer Institute (NCI)Phase 1 Recruiting32 enrolled